Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.01 USD
179.72 M USD
324.26 M USD
61.89 M
About Innoviva, Inc.
Sector
CEO
Pavel Raifeld
Headquarters
Burlingame
Website
Founded
1996
FIGI
BBG000CG9XT7
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of INVA is 19.15 USD — it has increased by 0.47% in the past 24 hours. Watch Innoviva, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Innoviva, Inc. stocks are traded under the ticker INVA.
INVA stock has fallen by −0.67% compared to the previous week, the month change is a −3.72% fall, over the last year Innoviva, Inc. has showed a 42.27% increase.
We've gathered analysts' opinions on Innoviva, Inc. future price: according to them, INVA price has a max estimate of 19.00 USD and a min estimate of 19.00 USD. Watch INVA chart and read a more detailed Innoviva, Inc. stock forecast: see what analysts think of Innoviva, Inc. and suggest that you do with its stocks.
INVA reached its all-time high on Jul 12, 2013 with the price of 34.61 USD, and its all-time low was 3.48 USD and was reached on Nov 21, 2008. View more price dynamics on INVA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
INVA stock is 1.55% volatile and has beta coefficient of 0.30. Track Innoviva, Inc. stock price on the chart and check out the list of the most volatile stocks — is Innoviva, Inc. there?
Today Innoviva, Inc. has the market capitalization of 1.20 B, it has increased by 0.85% over the last week.
Yes, you can track Innoviva, Inc. financials in yearly and quarterly reports right on TradingView.
Innoviva, Inc. is going to release the next earnings report on Feb 5, 2025. Keep track of upcoming events with our Earnings Calendar.
INVA earnings for the last quarter are 0.02 USD per share, whereas the estimation was 0.27 USD resulting in a −92.45% surprise. The estimated earnings for the next quarter are 0.37 USD per share. See more details about Innoviva, Inc. earnings.
Innoviva, Inc. revenue for the last quarter amounts to 89.51 M USD, despite the estimated figure of 76.91 M USD. In the next quarter, revenue is expected to reach 86.80 M USD.
INVA net income for the last quarter is 1.21 M USD, while the quarter before that showed −34.69 M USD of net income which accounts for 103.50% change. Track more Innoviva, Inc. financial stats to get the full picture.
No, INVA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 23, 2024, the company has 112.00 employees. See our rating of the largest employees — is Innoviva, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Innoviva, Inc. EBITDA is 201.10 M USD, and current EBITDA margin is 46.13%. See more stats in Innoviva, Inc. financial statements.
Like other stocks, INVA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Innoviva, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Innoviva, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Innoviva, Inc. stock shows the buy signal. See more of Innoviva, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.